Young-Hwan Koh
Overview
Explore the profile of Young-Hwan Koh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Kim T, Woo S, Chun J, Shin H, Cho Y, et al.
Cancer Res Treat
. 2024 Dec;
PMID: 39701089
Purpose: This study aims to assess the clinical outcomes of hypofractionated proton beam therapy (PBT) for extrahepatic cholangiocarcinoma (EHCC) and to investigate the optimal sequencing for combining PBT with chemotherapy....
2.
Kim B, Park H, Kim T, Koh Y, Hong J, Cho Y, et al.
JHEP Rep
. 2024 Mar;
6(4):100991.
PMID: 38463541
Background And Aims: Nivolumab was the first immune checkpoint inhibitor approved for hepatocellular carcinoma (HCC). External beam radiation therapy (EBRT) is locally effective and may enhance the effectiveness of immunotherapy....
3.
Kim T, Kim B, Cho Y, Koh Y, Park J
J Liver Cancer
. 2023 Jul;
23(2):330-340.
PMID: 37488926
Background/aim: Radiotherapy (RT) is an effective local treatment for hepatocellular carcinoma (HCC). However, whether additional RT is safe and effective in patients with advanced HCC receiving atezolizumab plus bevacizumab remains...
4.
Kim T, Woo S, Lee W, Chun J, Cho Y, Kim B, et al.
Cancers (Basel)
. 2022 Nov;
14(22).
PMID: 36428654
Forty-seven patients with intrahepatic cholangiocarcinoma (IHCC) who received proton beam therapy (PBT) were analyzed to evaluate the clinical efficacy and safety of hypofractionated PBT in patients with inoperable or recurrent...
5.
Kim T, Kim B, Park J, Cho Y, Koh Y, Chun J, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139604
To evaluate the efficacy of proton beam therapy (PBT) as an initial treatment in treatment-naïve hepatocellular carcinoma (HCC) patients and to assess the prognostic significance of albumin-bilirubin (ALBI) grade, 46...
6.
Kim T, Park J, Kim B, Oh E, Youn S, Moon S, et al.
Front Oncol
. 2020 May;
10:542.
PMID: 32411594
Proton beam has an excellent depth dose distribution due to its unique physical properties, and thus proton beam therapy (PBT) has been tried and showed promising outcomes in hepatocellular carcinoma...
7.
Choi S, Jeon A, Kim M, Lee Y, Im J, Koh J, et al.
Front Oncol
. 2019 Oct;
9:875.
PMID: 31572675
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal malignant tumor and more than 50% patients are diagnosed at metastatic stage. The preclinical model systems that reflect the genetic heterogeneity of...
8.
Kim T, Park J, Kim B, Kim H, Moon S, Kim S, et al.
Cancers (Basel)
. 2019 Feb;
11(2).
PMID: 30781391
To evaluate the role of risk-adapted proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients, a total of 243 HCC patients receiving risk-adapted PBT with three dose-fractionation regimens (regimen A...
9.
Kim T, Park J, Kim B, Kim D, Moon S, Kim S, et al.
Oncotarget
. 2018 Feb;
9(3):4034-4043.
PMID: 29423102
Objective: To evaluate the optimal time of tumour response and effectiveness of hypofractionated proton beam therapy (PBT) for hepatocellular carcinoma (HCC). Results: Overall, treatment was well tolerated with no grade...
10.
Kim D, Park J, Kim T, Kim B, Moon S, Kim S, et al.
Radiother Oncol
. 2016 Dec;
122(1):122-129.
PMID: 28034460
Purpose: To evaluate clinical effectiveness and safety of simultaneous integrated boost-proton beam therapy (SIB-PBT) in hepatocellular carcinoma (HCC) patients with tumour vascular thrombosis (TVT). Material And Methods: Forty-one HCC patients...